Menu +

New Research on Corcept's Korlym® for Patients with Cushing's Syndrome to be Presented at ICE/ENDO 2014

New data includes results of a long-term extension phase of Corcept’s multicenter, open-label SEISMIC study

Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, today announced that new clinical research on Korlym® (mifepristone) will be presented at the joint meeting of the International Society of Endocrinology and the Endocrine Society (ICE/ENDO 2014).

The research, including results of a long-term extension phase of Corcept’s multicenter, open-label SEISMIC study of Korlym, will be presented at the conference, taking place at the McCormick Place West Convention Center in Chicago from June 21-24. Korlym is a once-daily oral treatment for patients with Cushing’s syndrome who have glucose intolerance and have failed or cannot have surgery.

“Cushing’s syndrome, which is caused by excessive cortisol activity, is a serious condition that has a debilitating impact on all aspects of patients’ lives. The disease often significantly affects patients’ metabolism, leading to extreme weight gain with abnormal fat deposits, impaired glycemic control including type 2 diabetes, muscle weakness and, commonly, psychiatric symptoms,” said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer. “Because Cushing’s syndrome may be a chronic disease, it is important to monitor patients taking Korlym over time. The long-term extension study of SEISMIC includes data from patients who had been receiving treatment for as long as 3.5 years.”

Cushing’s syndrome is the result of excessive cortisol activity throughout the body. Cortisol is a hormone made in the adrenal glands that performs vital tasks such as regulating the metabolism of proteins, carbohydrates and fats. Cushing’s syndrome afflicts 20,000 people in the United States, with approximately 3,000 to 4,000 new cases each year. Approximately half of these patients are cured by surgery.

The following abstracts highlight new research on mifepristone:

 Date  Session  Time  Poster  Number  Title  Authors
 June 21,  2014
 0R02-2 Late‐Night Salivary Cortisol for the Diagnosis of Recurrent Cushing's Disease: Evidence of Clinical Benefit from Early Detection Ty Brian Carroll, MD;
Bradley R Javorsky, MD;
James W Findling, MD
 SAT-0671 Clinical Management in a Female with Persistent Cushing's Disease Treated with Mifepristone for Four Years Elizabeth E King, MD;
Simone M Howell, RN, CCRA
 June 22,  2014
 SUN-0750 Effect of Mifepristone on Cushing's syndrome Secondary to Bilateral Adrena Adenomas: A Case Presentation Vijay Babu Balakrishnan;
Pankaj Sharda, MBBS, MD;
Elias Said Siraj, MD
 June 23,  2014
 MON-0439 Improved Activities of Daily Living, Normal Mood and Quality of Life: 4 Years of Treatment Data in a Premenopausal Woman with Cushing's Disease Daphne T Adelman, BSN, MBA;
Simone M Howell, RN, CCRA
 MON-0592 A Case Report of a 37 y/o Woman Diagnosed with Cushing's Disease Presenting As Pituitary Apoplexy after Multiple Treatment Failures Effectively Responds to Mifepristone Howard A Brand, MD;
Kimberly Calcagno, MA;
Michele Lamerson, RN, MS, CPNP
 MON-0595 Discontinuation of Insulin, Oral Antidiabetic and Antihypertensive Medications in a Patient with Cushing's Disease Following Mifepristone (MIFE) Therapy Kevin C.J. Yuen, MD, FRCP (UK);
Harold I Magazine, PhD
 MON-0598 Mifepristone for Refractory Cushing's Syndrome in a Patient with CKD Hyperkalemia Undergoing Surgical Exodontia and Weight Loss: Recommendations for Clinical/Biochemical Monitoring and Perioperative Dosing Audrey Elisabeth Arzamendi, MD;
Alison Marie Semrad, DO
 MON-0663 Persistent Weight Loss in Patients Treated with Mifepristone (MIFE) for Cushing's Syndrome: Results from the Seismic & Long Term Extension Studies Henry G. Fein, MD;
T. Brooks Vaughan III, MD;
Coleman Gross; Dat Nguyen

About Corcept Therapeutics Incorporated

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that regulate the effects of the stress hormone cortisol on the body. The FDA has approved the company’s first drug, Korlym® (mifepristone) 300 mg Tablets, a glucocorticoid receptor antagonist, as a once-daily oral treatment for hyperglycemia secondary to endogenous Cushing’s syndrome in adult patients with glucose intolerance or diabetes mellitus type 2 who have failed surgery or are not candidates for surgery. Corcept is exploring mifepristone (the active ingredient in Korlym) as a treatment for triple-negative breast cancer with a multi-center, Phase I clinical study currently underway in patients with metastatic or locally advanced unresectable breast cancer. It is also supporting investigator-led clinical studies of mifepristone in the treatment of ovarian cancer and castration-resistant prostate cancer. The company has a portfolio of selective glucocorticoid-receptor (GR) antagonists that block the effects of cortisol but not progesterone. It owns or has licensed extensive intellectual property covering the use of GR antagonists, including mifepristone, in the treatment of a wide variety of metabolic and psychiatric disorders and triple-negative breast cancer. It also holds composition of matter patents for its selective GR antagonists.

Investor Contact

Charles Robb, Corcept Therapeutics Incorporated
Chief Financial Officer

Media Contact

Brian Baxter for Corcept
Lazar Partners Ltd.

You are now leaving this website. If you would like to continue, click Continue.
Cancel Continue